Retatrutide and Tirzepatide are supplied by RS Bio Labs strictly as laboratory research materials for qualified scientific personnel. They are not approved, intended or authorised for human consumption, self-administration, diagnostic, therapeutic or veterinary use. All figures referenced here are drawn from published preclinical or clinical-trial literature and do not constitute medical advice, dosing guidance or any statement of safety in an unapproved setting.
The core difference
Both compounds are synthetic, fatty-acid-conjugated, long-acting peptides engineered to hit more than one incretin receptor at a time. The line between them is simple: how many receptors each one activates.
- Tirzepatide is a dual agonist — it engages the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R).
- Retatrutide is a triple agonist — it engages those same two receptors plus the glucagon receptor (GCGR).
That third target is not a minor addition. GLP-1 and GIP activity mainly reduce energy intake — appetite suppression, slowed gastric emptying and glucose-dependent insulin secretion. Glucagon-receptor activation works on the other side of the ledger: in research models it raises resting energy expenditure and drives hepatic lipid mobilisation. Retatrutide is therefore studied as a compound that lowers intake and raises expenditure simultaneously — something a dual agonist cannot do. For a fuller breakdown of the three receptor systems, see GLP-1 vs GIP vs Glucagon agonists.
Side-by-side comparison
The table below sets the two compounds against each other on the properties most often referenced in the research literature.
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon (triple) | GIP + GLP-1 (dual) |
| Developer code | LY3437943 | LY3298176 |
| Brand names | None — investigational | Mounjaro / Zepbound |
| Half-life | ~6 days | ~5 days |
| Peak trial weight change | ~24.2% (TRIUMPH-1, Ph2, 48 wk) | ~22.5% (SURMOUNT-1, Ph3, 72 wk) |
| Regulatory status | Investigational — not approved | FDA-approved (T2D & obesity) |
Why the glucagon arm matters
Tirzepatide's dual mechanism was itself a leap over single GLP-1 agonists such as Semaglutide: adding GIP activity to GLP-1 lifted pivotal-trial weight reduction from roughly 15% into the low-20% range. Retatrutide asks the next question — what happens when you add a third, mechanistically opposite pathway?
The glucagon receptor is best known for raising blood glucose, which is why combining it with strong insulinotropic (GIP/GLP-1) activity is central to the design: the incretin arms are intended to offset glucagon's glycaemic effect while its thermogenic and lipolytic effects are retained. In preclinical and early clinical work this combination is associated with increased energy expenditure and pronounced reductions in hepatic fat. It is the reason Retatrutide is investigated not only in obesity but in metabolic dysfunction-associated steatohepatitis (MASH), where liver-fat mobilisation is the endpoint of interest.
Retatrutide reached ~24.2% mean weight reduction at 12 mg by week 48 of the Phase 2 TRIUMPH-1 trial (Jastreboff et al., NEJM 2023) — and the curve had not plateaued. Tirzepatide reached ~22.5% at its top dose over the longer 72-week Phase 3 SURMOUNT-1 trial. Retatrutide's figure is larger over a shorter window, but it comes from an earlier-phase, smaller programme, so the two are not strictly like-for-like.
What the difference means in a research context
For laboratory work the distinction is concrete rather than abstract. Studies designed around receptor pharmacology, binding assays or metabolic-model readouts will treat the two compounds as representatives of different mechanistic classes — dual versus triple agonism — not as interchangeable stand-ins. Tirzepatide provides a well-characterised, regulator-approved dual-agonist reference point with a deep published dataset; Retatrutide provides the frontier triple-agonist comparator whose glucagon component introduces variables (energy expenditure, hepatic lipid handling) that a dual agonist does not.
Practically, handling is near-identical. Both arrive as sterile lyophilised (freeze-dried) powder in sealed vials measured in milligrams, both are reconstituted with bacteriostatic water before use, both are kept refrigerated, and both suit a once-weekly research schedule thanks to their multi-day half-lives — Retatrutide's ~6 days against Tirzepatide's ~5 days.
Which for your research?
There is no universally "better" compound — only the one that fits the question. If a protocol needs a validated, approved dual-incretin benchmark, Tirzepatide is the natural reference. If the research targets the added glucagon pathway — thermogenesis, resting energy expenditure or hepatic lipid endpoints — Retatrutide is the compound built for it, and many comparative study designs run the two in parallel precisely to isolate the contribution of the glucagon arm. As of 2026 Retatrutide remains investigational and unapproved by the MHRA, FDA or any regulator; Tirzepatide is approved as a medicine but is supplied here only as a research reagent. Everything above is a scientific reference drawn from published literature — products sold by RS Bio Labs are for in vitro laboratory work and are not for human use.